Comparing ticagrelor and prasugrel for heart disease treatment
Official title: Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors: Pharmadodynamic Comparison Between Prasugrel and Ticagrelor Monotherapy. The Switching Antiplatelet -7 (SWAP-7) Study
Run by University of Florida · NCT06691191 · Data updated 2026-11-12
This study is testing whether ticagrelor or prasugrel is better at preventing bleeding and heart issues in patients with heart disease who have already been on another type of treatment.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 48 (estimated) |
| Sponsor | University of Florida Academic / other |
| Locations | 1 site (Jacksonville, Florida) |
| Status | Recruiting |
| Started | January 8, 2025 |
| Main results expected | August 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | February 5, 2026 |
| Trial ID | NCT06691191 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 who have been on dual antiplatelet therapy for at least 90 days after a percutaneous coronary intervention.
✕Probably not a fit
Patients with a history of stent thrombosis, recent PCI, or those over 75 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to compare the effectiveness of ticagrelor and prasugrel as single antiplatelet therapies after patients have undergone dual antiplatelet therapy for coronary artery disease. It will evaluate the pharmacodynamic profiles of both medications to determine if they are comparable in reducing bleeding events without increasing the risk of heart-related complications. The study will involve patients aged 18 to 75 who have been on dual antiplatelet therapy for at least 90 days following a percutaneous coronary intervention. Participants will be randomly assigned to receive either ticagrelor or prasugrel for the duration of the study.
Why it matters
Potential benefit: If successful, this study could help identify a safer and more effective antiplatelet therapy for patients with coronary artery disease.
How similar studies have gone: Previous studies have shown success with similar approaches, particularly with ticagrelor monotherapy demonstrating reduced bleeding events without increasing ischemic risk.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: 1. Patients on DAPT with aspirin plus prasugrel 10 mg or ticagrelor 90 mg bid as per standard of care at least 90 days after PCI. 2. Age between 18 and 75 years old 3. Able to provide written informed consent Exclusion criteria: 1. Prior history of stent thrombosis 2. PCI within 90 days. 3. History of stroke/TIA 4. Age \> 75 years old 5. Weight \< 60 kg 6. History of intracranial hemorrhage 7. On treatment with any oral anticoagulant or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis) 8. Patients with known coagulation disorders 9. Known severe hepatic impairment 10. Hypersensitivity to prasugrel or ticagrelor 11. Pregnant and breastfeeding persons \[persons of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study\]. If the potential subject is a person of childbearing potential, a pregnancy test will be done. If the subject is pregnant, participation in this study will end.
Where it's running
-
University of Florida Jacksonville
Jacksonville, Florida, United States Recruiting
Study contacts
- Principal investigator: Francesco Franchi, MD — University of Florida College of Medicine Jacksonville
- Study coordinator: Francesco Franchi, MD
- Email: francesco.franchi@jax.ufl.edu
- Phone: 9042445515
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.